Specifically, in cancers with over-activated MVA pathway, notably gallbladder and breast cancers, use HMGCR inhibitors, such as statins, sensitizes tumor cells to chemo- or HER2-targeted therapies, respectively, and reduces tumor growth and prolong survival time of gallbladder cancer-bearing mice [146, 147]. This evidence concerns the gene ERBB2 and breast cancer.